Guangzhou, China / Jeddah, Saudi Arabia – September 15,
2025 – Bio-Thera Solutions Inc. (688177:SH), a commercial-stage biopharmaceutical company developing a pipeline of innovative therapies and biosimilars and Jamjoom Pharmaceuticals
Factory Company (Jamjoom Pharma), one of the fastest-growing pharmaceutical
companies in the Middle East and Africa, announced the signing of a strategic
commercialization agreement for BAT2306, a
biosimilar referencing Cosentyx?.
Under the agreement, Jamjoom Pharma will obtain the exclusive
rights to commercialize BAT2306 - a proposed biosimilar to Novartis’
Cosentyx? (secukinumab) - across the Middle East and North Africa (MENA)
region. Jamjoom Pharma will manage regulatory submissions, market access, and
commercialization in MENA, while Bio-Thera will oversee product development and
global manufacturing from its state-of-the-art facilities in Guangzhou, China.
"This collaboration is a strategic milestone for
Jamjoom Pharma and a testament to our mission of broadening access to advanced
biologics in the MENA region,”said Tarek Hosni, Chief Executive Officer of
Jamjoom Pharma. "By joining forces with Bio-Thera, we are combining
world-class biosimilar development with Jamjoom’s deep regional expertise,
strong commercial capabilities, and commitment to delivering high-quality,
affordable therapies. This agreement strengthens our leadership in the
biopharmaceutical sector and reinforces our role as a trusted partner in
improving patient outcomes."
"Bio-Thera is committed to bringing affordable
medicines to patients in need around the world," said Bert Thomas, Senior
Vice President of Business Development. "Partnering with JamJoom Pharma to bring BAT2306 to patients in the MENA
region is a demonstration of that commitment. We are proud to partner with Jamjoom Pharma and look forward to a
successful collaboration."
About Bio-Thera Solutions
Bio-Thera Solutions,
Ltd., a leading innovative, global biopharmaceutical company in Guangzhou,
China, is dedicated to researching and developing novel therapeutics for the
treatment of cancer, autoimmune, cardiovascular, eye diseases, and other severe
unmet medical needs, as well as biosimilars for existing, branded biologics to
treat a range of cancer and autoimmune diseases. As a leader in next generation
antibody discovery and engineering, the company has advanced multiple
candidates into late-stage development, including five approved products:
Qletli? (adalimumab) in China and the UK, BETAGRIN? (bevifibatide citrate
injection) in China, STARJEMZA? (ustekinumab) in the US and Usymro?
(ustekinumab) in EU, and TOFIDENCE?/BAT1806 (tocilizumab) and AVZIVI?
(bevacizumab-tnjn) in the US and in EU, a/k/a POBEVCY? in China. In addition,
the company has more than 20 promising candidates in clinical trials, focusing
on immuno-oncology in the post-PD-1 era and targeted therapies such as
antibody-drug conjugates (ADCs). For more information, please visit
m.helizi.cn/en/ or follow us on X (@bio_thera_sol) and WeChat (Bio-Thera).
About Jamjoom Pharma “Jamjoom Pharmaceuticals Factory Company
Jamjoom Pharma is a leading pharmaceutical organization committed to enhancing the quality of life through the development, manufacturing, and distribution of high-quality medicines and consumer healthcare products. Headquartered in Saudi Arabia, the company was established back in 2000 and is tirelessly operating to support the Saudi Vision 2030 to reinforce the public healthcare system. With a strong focus on patient-centered care, Jamjoom Pharma serves diverse markets across Middle East & Africa, with a bold ambition for more expansion, providing effective solutions in key therapeutic areas (including ophthalmology, dermatology, cardiometabolic, gastrointestinal, and general medicine). Through its state-of-the-art facilities and established distribution channels across the MEA region and dedication to regulatory excellence, Jamjoom Pharma continues to deliver products that meet the highest standards of safety, efficacy, and quality, improving health outcomes for millions of people.
Cautionary Note Regarding Forward-Looking Statements
This news release
contains certain forward-looking statements relating to BAT2306 or the product
pipelines in general of Bio-Thera Solutions. Readers are strongly cautioned
that reliance on any forward-looking statements involves known and unknown
risks and uncertainties. The forward-looking statements include, among others,
those containing “could,” “may,” “should,” “will,” “would,” “anticipate,”
“believe,” “plan,” “promising,” “potentially,” or similar expressions. They
reflect the company’s current views with respect to future events that are
based on what the company believes are reasonable assumptions in view of
information currently available to Bio-Thera Solutions, and are not a guarantee
of future performance or developments. Actual results and events may differ
materially from information contained in the forward-looking statements as a
result of a number of factors, including, but not limited to, risks and
uncertainties inherent in pharmaceutical research and development, such as the
uncertainties of pre-clinical and clinical studies. Other risks and
uncertainties include challenges in obtaining regulatory approvals, manufacturing,
marketing, competition, intellectual property, product efficacy or safety,
changes in global healthcare situation, changes in the company’s financial
conditions, and changes to applicable laws and regulations, etc.
Forward-looking statements contained herein are made only as of the date of
their initial publication. Unless required by laws or regulations, Bio-Thera
Solutions undertakes no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events, changes in
the company’s views or otherwise.
Jamjoom Pharma Disclaimer
All information included in this document is for general use only and has not been independently verified, nor does it constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in the Kingdom of Saudi Arabia, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of Jamjoom Pharmaceuticals. No warranty, express or implied, is made, and no reliance should be placed by any person or any legal entity for any purpose on the information and opinions contained in this document, or its fairness, accuracy, completeness or correctness.
This document may include statements that are, or may be deemed to be, “forward-looking statements” with respect to the Company’s financial position, results of operations and business. Information on the Company’s plans, intentions, expectations, assumptions, goals and beliefs are for general update only and do not constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation or recommendation to buy or subscribe for any securities in any jurisdiction, or an offer or invitation or recommendation in respect of buying, holding or selling any securities of Jamjoom Pharmaceuticals.
